Skip to main content

Emmanuel Benjamin Walter, MD

Professor of Pediatrics
Affiliate, Duke Global Health Institute
Member in the Duke Clinical Research Institute
Member of the Duke Human Vaccine Institute
Campus mail: 2608 Erwin Road, Suite 210, Durham, NC 27705
Phone: (919) 620-5374
Email address: walte002@mc.duke.edu

Dr. Emmanuel Walter, MD, MPH, Professor of Pediatrics, serves as the Duke Human Vaccine Institute (DHVI) Chief Medical Officer and directs the Duke Vaccine and Trials Unit. In these roles, Dr. Walter provides strategic and operational leadership for clinical research conducted at the Institute.  In addition, he provides oversight of regulatory compliance for DHVI clinical research activities.

Dr. Walter has dedicated his career to advancing research and clinical practice in vaccinology, infectious diseases, and child health. He currently serves as the principal investigator for the Duke Clinical Core of the Collaborative Influenza Vaccine Innovations Centers (CIVICs) funded by the National Institute of Allergy and Infectious Diseases (NIAID).  The goal of this work is to evaluate promising next generation influenza vaccine candidates in Phase I and Phase I/II clinical trials and human challenge studies.  He is the Duke Co-Principal Investigator for the NIAID Vaccine and Treatment Evaluation Unit (VTEU) which conducts clinical trials of vaccines and treatments for infectious diseases.  He is also the Duke Principal Investigator for the CDC-funded Clinical Immunization Safety Assessment Project which conducts studies to identify risk factors and preventive strategies for adverse events following immunization, particularly in special populations. Lastly, he is the Principal Investigator for a CDC-funded project to further understand and reduce disparities in vaccine coverage among rural adolescents.

Dr. Walter's focused area of interest include vaccine development, vaccine safety, vaccine coverage, prevention and treatment of infectious diseases.

Education and Training

  • M.P.H., University of North Carolina - Chapel Hill, 1992
  • M.D., University of Maryland, College Park, 1983
  • B.S., University of Notre Dame, 1979

Selected Grants and Awards

Publications

Frenck, Robert W., Nicola P. Klein, Nicholas Kitchin, Alejandra Gurtman, Judith Absalon, Stephen Lockhart, John L. Perez, et al. “Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.” N Engl J Med, May 27, 2021. https://doi.org/10.1056/NEJMoa2107456.

Full Text

Glenn, Dorey A., Anisha Hegde, Elizabeth Kotzen, Emmanuel B. Walter, Abhijit V. Kshirsagar, Ronald Falk, and Amy Mottl. “Systematic Review of Safety and Efficacy of COVID-19 Vaccines in Patients With Kidney Disease.” Kidney Int Rep 6, no. 5 (May 2021): 1407–10. https://doi.org/10.1016/j.ekir.2021.02.011.

Full Text

Guptill, J. T., S. M. Raja, V. C. Juel, E. B. Walter, M. Cohen-Wolkowiez, H. Hill, E. Sendra, B. Hauser, P. Jackson, and G. K. Swamy. “Safety, Tolerability and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B.” Antimicrob Agents Chemother, April 19, 2021. https://doi.org/10.1128/AAC.02329-20.

Full Text

Abate, Getahun, Jack T. Stapleton, Nadine Rouphael, Buddy Creech, Jason E. Stout, Hana M. El Sahly, Lisa Jackson, et al. “Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease.” Clin Infect Dis 72, no. 7 (April 8, 2021): 1127–37. https://doi.org/10.1093/cid/ciaa252.

Full Text

Schmader, Kenneth E., Christine K. Liu, Theresa Harrington, Wes Rountree, Heidi Auerbach, Emmanuel B. Walter, Elizabeth D. Barnett, et al. “Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial.” Jama Netw Open 4, no. 1 (January 4, 2021): e2031266. https://doi.org/10.1001/jamanetworkopen.2020.31266.

Full Text

Nachbagauer, Raffael, Jodi Feser, Abdollah Naficy, David I. Bernstein, Jeffrey Guptill, Emmanuel B. Walter, Franceso Berlanda-Scorza, et al. “A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.” Nat Med 27, no. 1 (January 2021): 106–14. https://doi.org/10.1038/s41591-020-1118-7.

Full Text

Jenks, Jennifer A., Cody S. Nelson, Hunter K. Roark, Matthew L. Goodwin, Robert F. Pass, David I. Bernstein, Emmanuel B. Walter, et al. “Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans.” Sci Transl Med 12, no. 568 (November 4, 2020). https://doi.org/10.1126/scitranslmed.abb3611.

Full Text

Hurst, Jillian H., Sarah M. Heston, Hailey N. Chambers, Hannah M. Cunningham, Meghan J. Price, Lilianna Suarez, Carter G. Crew, et al. “SARS-CoV-2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) Study.” Clin Infect Dis, November 3, 2020. https://doi.org/10.1093/cid/ciaa1693.

Full Text

Hurst, Jillian H., Sarah M. Heston, Hailey N. Chambers, Hannah M. Cunningham, Meghan J. Price, Liliana Suarez, Carter G. Crew, et al. “SARS-CoV-2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) Study.” Medrxiv, September 1, 2020. https://doi.org/10.1101/2020.08.18.20166835.

Full Text

Brady, Allison M., Emmanuel B. Walter, Lauri E. Markowitz, Elizabeth R. Unger, and Gitika Panicker. “Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity.” In Hum Vaccin Immunother, 16:1802–7, 2020. https://doi.org/10.1080/21645515.2019.1706410.

Full Text

Pages